Rapid engineering of SARS-CoV-2 therapeutic antibodies to increase breadth of neutralization including BQ.1.1, CA.3.1, CH.1.1, XBB.1.16, and XBB.1.5Kevin C. Entzminger, Toshiaki Maruyama|Antibody Therapeutics|2023Cited by 11